In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for AKB-9778. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AKB-9778 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [2]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for DCC-2036. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DCC-2036 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [3]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for Altiratinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Altiratinib through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [4]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for CEP-11981. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEP-11981 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [5]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for (4-Phenoxy-phenyl)-quinazolin-4-yl-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-Phenoxy-phenyl)-quinazolin-4-yl-amine through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [6]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [8]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for A-420983. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-420983 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [7]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for ABTAA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABTAA through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [9]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for AP-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AP-101 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [10]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Angiopoietin 1 receptor (TEK) is a therapeutic target for ARRY-614. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARRY-614 through regulating the expression of Angiopoietin 1 receptor (TEK).			[1], [11]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for VB-111. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VB-111 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [13]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [14]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for DE-098. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DE-098 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [15]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [16]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for 2-aminophenoxazine-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-aminophenoxazine-3-one through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [17]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-103. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-103 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [18]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for F61F12. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of F61F12 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [19]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for ISIS 17020. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 17020 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS).			[12], [20]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator BAX (BAX) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator BAX (BAX).			[21], [22]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [24]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [25]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [26]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [27]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [28]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [29]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [30]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [31]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [32]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [33]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [34]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[18], [23]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [35]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[5], [23]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [36]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [37]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [38]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [39]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [40]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [41]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [42]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [43]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [45]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [46]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [44]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [47]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [48]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2).			[23], [49]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATM serine/threonine kinase (ATM) is a therapeutic target for KU-60019. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KU-60019 through regulating the expression of ATM serine/threonine kinase (ATM).			[5], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATM serine/threonine kinase (ATM) is a therapeutic target for AZD0156. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD0156 through regulating the expression of ATM serine/threonine kinase (ATM).			[50], [51]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATM serine/threonine kinase (ATM) is a therapeutic target for AZD1390. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD1390 through regulating the expression of ATM serine/threonine kinase (ATM).			[5], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATM serine/threonine kinase (ATM) is a therapeutic target for M3541. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M3541 through regulating the expression of ATM serine/threonine kinase (ATM).			[5], [50]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATM serine/threonine kinase (ATM) is a therapeutic target for CGK733. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGK733 through regulating the expression of ATM serine/threonine kinase (ATM).			[50], [52]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATP-citrate synthase (ACLY) is a therapeutic target for Bempedoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bempedoic acid through regulating the expression of ATP-citrate synthase (ACLY).			[53], [54]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATP-citrate synthase (ACLY) is a therapeutic target for (-)-hydroxycitrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (-)-hydroxycitrate through regulating the expression of ATP-citrate synthase (ACLY).			[53], [55]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	ATP-citrate synthase (ACLY) is a therapeutic target for SB-201076. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-201076 through regulating the expression of ATP-citrate synthase (ACLY).			[53], [56]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1).			[57], [58]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1).			[57], [59]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1).			[57], [60]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Abacavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abacavir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [62]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Acyclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acyclovir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [63]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Adefovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Adefovir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Afatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Afatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [65]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Alfuzosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alfuzosin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [66]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Apatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [67]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Apixaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apixaban through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [68]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Baricitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Baricitinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [69]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Bicalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bicalutamide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [70]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Binimetinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Binimetinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [71]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Brigatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brigatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [72]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Bupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bupropion through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [73]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Canagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Canagliflozin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [74]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cephalothin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cephalothin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cerivastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerivastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Chlorothiazide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chlorothiazide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [77]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cholic acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cimetidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cimetidine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [79]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ciprofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ciprofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [80]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cisplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cisplatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cladribine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cladribine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Clofarabine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clofarabine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [82]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cyclosporine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclosporine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dabrafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dabrafenib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [83]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dactinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dactinomycin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [84]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Daidzein. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Daidzein through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dehydroepiandrosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroepiandrosterone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dehydroepiandrosterone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroepiandrosterone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Delavirdine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Delavirdine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Deoxycholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Deoxycholic acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Diclofenac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diclofenac through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [88]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dipyridamole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dipyridamole through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Dirithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dirithromycin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Docetaxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Docetaxel through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Eltrombopag. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eltrombopag through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [91]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Empagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Empagliflozin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Entacapone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Entacapone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [93]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Entecavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Entecavir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [94]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Epirubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epirubicin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Erythromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [95]

In total 2 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Estrone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [96]
	Breast cancer resistance protein (ABCG2) is a therapeutic target for Estrone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Etoposide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etoposide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [98]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ezetimibe. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ezetimibe through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [99]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Fluvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluvastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [100]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Folic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folic acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [101]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ganciclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ganciclovir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [102]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Glibenclamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glibenclamide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [103]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Glutathione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glutathione through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [104]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Grepafloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Grepafloxacin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [105]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Hesperetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hesperetin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [106]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Hydroxychloroquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxychloroquine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [107]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Hypericin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hypericin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [108]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Idarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Idarubicin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [109]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Idelalisib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Idelalisib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [110]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Imatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [111]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Irinotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Irinotecan through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [112]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Lamivudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lamivudine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [113]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Lapatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lapatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [114]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Leflunomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Leflunomide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [115]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Lopinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lopinavir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Menadione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Menadione through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [116]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Mercaptopurine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mercaptopurine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Methotrexate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [117]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Mitoxantrone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mitoxantrone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [118]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Moxidectin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Moxidectin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [119]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Mycophenolate mofetil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [120]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Nelfinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nelfinavir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Nicardipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicardipine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Nifurtimox. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nifurtimox through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [121]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Nilotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nilotinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [122]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Nitrofurantoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitrofurantoin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [123]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Norfloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norfloxacin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [124]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Olmesartan medoxomil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olmesartan medoxomil through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Oxaliplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxaliplatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [125]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Palbociclib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palbociclib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [126]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pantoprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pantoprazole through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [127]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pazopanib hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pazopanib hydrochloride through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [128]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pemetrexed. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pemetrexed through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [129]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pirarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirarubicin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [130]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pitavastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pitavastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [89]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pitavastatin calcium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pitavastatin calcium through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [131]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ponatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ponatinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [132]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pravastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pravastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Prazosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prazosin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [133]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pyrimethamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pyrimethamine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rabeprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rabeprazole through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [135]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Raltitrexed. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Raltitrexed through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Regorafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Regorafenib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Reserpine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Reserpine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Riboflavin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riboflavin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [137]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rifampicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rifampicin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Riluzole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riluzole through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [138]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Riociguat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riociguat through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rivaroxaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rivaroxaban through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [139]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rosiglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosiglitazone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [140]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rosuvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosuvastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [141]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Saquinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saquinavir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [142]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Simvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simvastatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [86]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Sofosbuvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sofosbuvir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 2 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Sulfasalazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfasalazine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [143]
	Breast cancer resistance protein (ABCG2) is a therapeutic target for Sulfasalazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfasalazine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [144]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Talazoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Talazoparib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [145]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Tenofovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [92]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Teriflunomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Teriflunomide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [107]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Testosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [146]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Tetracycline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tetracycline through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Thioguanine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thioguanine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [64]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Topotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Topotecan through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [147]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Trimetrexate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimetrexate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Vandetanib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vandetanib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [148]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Verteporfin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Verteporfin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [149]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Vinblastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vinblastine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [90]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Vincristine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vincristine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Zidovudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zidovudine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for AG 337. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG 337 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Belotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Belotecan through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [150]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for BNP-1350. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BNP-1350 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Butyrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Butyrate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [151]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Camptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Camptothecin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [152]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Exatecan mesylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Exatecan mesylate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Glycocholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glycocholic acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [78]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for J-107088. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of J-107088 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Phenethyl isothiocyanate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenethyl isothiocyanate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Tenofovir alafenamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir alafenamide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [153]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Uric acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Uric acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [154]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for 9-Aminocamptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Aminocamptothecin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Bisantrene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisantrene through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for BN-80915. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BN-80915 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for C-1311. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-1311 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [155]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Cholesterol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cholesterol through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [95]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Flavopiridol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flavopiridol through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [156]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Genistein. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Genistein through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [97]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Gimatecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gimatecan through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for HPPH. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HPPH through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [157]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Ortataxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ortataxel through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Oxfendazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxfendazole through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [158]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Phosphatidylserine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phosphatidylserine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [159]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Piritrexim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Piritrexim through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [134]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Quinacrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinacrine through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [75]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for SJG-136. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SJG-136 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [160]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for SN-38. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SN-38 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [161]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for UCN-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UCN-01 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Benzo(a)pyrene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzo(a)pyrene through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Benzoylphenylurea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzoylphenylurea through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [162]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for CP-724714. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-724714 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [163]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Mycophenolic acid glucuronide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolic acid glucuronide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [120]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for YP-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YP-005 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [164]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for AG1478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1478 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [81]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for AZD-1152-HQPA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-1152-HQPA through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [165]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Azidothymidine monophosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azidothymidine monophosphate through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [166]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [167]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Coumestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Coumestrol through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [85]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Enrofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enrofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [168]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Homocamptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Homocamptothecin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [169]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for JNJ 7706621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ 7706621 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [170]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for N-desethyl sunitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-desethyl sunitinib through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [171]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Pancratistatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pancratistatin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [172]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Protoporphyrin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Protoporphyrin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Puromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Puromycin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Scutellarin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Scutellarin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [173]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Chrysin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chrysin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [76]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Estradiol-17beta-glucuronide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol-17beta-glucuronide through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [174]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Hematoporphyrin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hematoporphyrin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [175]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Becatecarin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Becatecarin through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [176]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Befloxatone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Befloxatone through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [177]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for E3040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E3040 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [166]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Lurtotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lurtotecan through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [87]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for NB-506. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NB-506 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [136]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Parabis. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Parabis through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [178]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Rhodamine 123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rhodamine 123 through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [179]

In total 1 mechanisms lead to this potential drug response				Drug Info
Response Summary	Breast cancer resistance protein (ABCG2) is a therapeutic target for Taurocholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Taurocholic acid through regulating the expression of Breast cancer resistance protein (ABCG2).			[61], [78]